Besides its potent activity against most major clinically relevant KIT mutations, several studies highlight ponatinib as a multi-targeted inhibitor, which acts as a pan-FGFR inhibitor in different FGFR-amplified or FGFR-mutated cancer cell lines [69]. This evidence concerns the gene KIT and cancer.